Historically, literature reviews have come to the conclusion that there is no association between alcohol use and prostate cancer incidence. However, … … READ MORE …
Filed under: Diagnosis, Risk | Tagged: alcohol, consumption, risk | 2 Comments »
-
-
-
-
-
-
- The "New" Prostate Cancer InfoLink has been developed to become a primary source of accurate, current, and topical information about prostate cancer for patients and their families.
A service of
Awards
Other PCI web sites
-
PCaI’s ASVSG
If you are on or thinking about active surveillance (AS) as a way to manage your low-risk prostate cancer, you may want to join Prostate Cancer International’s Active Surveillance Virtual Support Group.
CureTalks on PCa
Our most recent CureTalk on Prostate Cancer (on February 21 this year) features Eli Van Allen, MD, of the Broad Institute and the Dana-Farber Cancer Center, talking about the new “Metastatic Prostate Cancer Project” and how you can become part of the solution.
For access to the full list of CureTalks on Prostate Cancer, please click here.
Disclaimer
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
-
Hot Posts …
- Does “AR gain” affect responses to drugs like abiraterone in men with CRPC?
- New guidelines for management of advanced prostate cancer
- The pros and cons of “screening” for prostate cancer
- More on familial and hereditary risk for prostate cancer
- Putting on weight … if you’ve had localized prostate cancer
- Ipatasertib meets one of two primary endpoints in Phase III trial
- RP vs. RT as first-line treatment for prostate cancer: that word “may” again
- Germline testing to assess risk for specific types of prostate cancer
- Importance of adding ADT to brachy boost therapy for men with unfavorable-risk prostate cancer
- Are you willing to talk about your late-stage mCRPC journey?
- Data from HERO trial reported — at virtual ASCO and in NEJM
- And now … FDA approves second PARP inhibitor for selected men with mCRPC
- FDA approves first PARP inhibitor for selected men with mCRPC
- Prostate cancer and coronavirus (COVID-19)
- Sipuleucel-T in management of favorable-risk prostate cancer: the ProVent trial
… and Archives
Blog at WordPress.com. WP Designer.
